AXR-270 demonstrated ‘statically and clinically meaningful improvement’ in patients with dry eye disease associated with meibomian gland dysfunction, according to a press release from AxeroVision.
In a phase 2, multicenter, randomized, double-masked trial, 129 patients were separated into three groups. Each group was treated for 3 weeks. The treatment groups were AXR-270 0.2% cream, AXR-270 2% cream and a vehicle control, the release said. Incidence of adverse events at day 22 was the primary outcome measure.
AXR-270 demonstrated improvement from baseline in eye dryness score (P <